title: Circadian variations of gastrointestinal mucosal damage detected with transnasal endoscopy in apparently healthy subjects treated with low-dose aspirin (ASA) for a short period.
abstract: OBJECTIVE
  In this study, transnasal endoscopy was used to observe the time-course changes of gastrointestinal mucosa with low-dose aspirin (ASA), and the preventive effect of rebamipide was compared with placebo.
  
  
  METHODS
  Twenty healthy H.pylori-negative subjects were divided between those receiving 100 mg aspirin with placebo, and those receiving 100 mg aspirin+300 mg rebamipide for 7 days daily. Transnasal endoscopy was performed at 0, 2, 6 and 24 hrs on the first day, and then on the third and seventh days.
  
  
  RESULTS
  Ulcers, in the duodenum at 24 hrs and in the antrum at 72 hrs, improved with continuous ASA. Erosions were mainly observed in the duodenum; erosions amounted to 14 at 3 days and 19 at 7 days in the placebo group. No ulcers and some erosions were mainly observed in the duodenum; erosions amounted to 5 at 3 days and 3 at 7 days in the rebamipide group.
  
  
  CONCLUSIONS
  In short-term gastrointestinal damage induced by ASA, damage was observed in the duodenum most frequently, and peak damage was at 24 hrs and 72 hrs. Almost all damage improved gradually in spite of continuous ASA. Rebamipide reduced the damage of low-dose aspirin-induced GI complications.
authors: Endoscopy Center, Tokyo Medical University Hospital, Tokyo 160-0023, Japan. t-kawai@tokyo-med.ac.jp
authors: Takashi
authors: T
authors: Kawai
authors: Tetsuya
authors: T
authors: Yamagishi
authors: Shinya
authors: S
authors: Goto
mesh_terms: D000328:Adult; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D002940:Circadian Rhythm; D004311:Double-Blind Method; D004724:Endoscopy; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology*; D008297:Male; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014456:Ulcer / Q000139:chemically induced / Q000188:drug therapy; D055815:Young Adult
chemical_list: D015363:Quinolones; C052785:rebamipide; D000409:Alanine; D001241:Aspirin